BIOCODEX
17.1.2024 18:10:26 CET | Business Wire | Press release
Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected for their clinical efficacy, in response to growing consumer demand for solutions to digestive health, woman’s health, brain health, joint care and immune system boosting.
Through this licensing agreement, which is accompanied by the acquisition of a 20% minority stake in My Health, Biocodex intends to reinforce its leadership in microbiota and round out its range of probiotics, such as Ultra Levure® (commercialized in Belgium as Enterol®) and Alflorex®, widely known in France and around the world for the treatment of digestive disorders.
On the strength of its recognized expertise among healthcare professionals and its presence in over 100 countries worldwide, Biocodex hopes to make a success of this strategic partnership and significantly accelerate My Health international sales development.
Nicolas Coudurier, CEO of Biocodex, is delighted with the deal: "My Health and Biocodex share a common vision: we are convinced of the key role played by the microbiota in everyone's health and well-being, and believe that many ailments, particularly in the digestive sphere, can be treated by scientifically based probiotics such as those developed by My Health. I'm looking forward to supporting the development of a promising young company like My Health and continuing to play our part in raising awareness among the general public and healthcare professionals of the growing importance of the microbiota to our health and well-being."
Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex. With our shared vision on the importance of microbiota solutions complemented by a joint dedication to innovation and science, we are excited to bring our solution for functional dyspepsia to many more countries, and with Biocodex as an expert in microbiota-targeted solutions, we found the perfect international partner to achieve this ambitious goal.”
About Biocodex
Biocodex, an independent, family-owned French pharmaceutical group founded in 1953, markets the probiotic strain Saccharomyces Boulardii CNCM I-745, a pioneer in the probiotic category and today No. 1 worldwide by value.
Biocodex is committed to improving the health and well-being of patients at every stage of their lives, focusing on three pillars: microbiota, women's health and orphan diseases. Its extensive product portfolio includes medicines, dietary supplements, medical devices and dermo-cosmetics.
The group has over 1,600 employees worldwide, 16 subsidiaries and is present in over 100 countries through its network of distributors; it generated sales of 501 million euros in 2022.
About My Health
My Health, an independent Belgian Biotech company, is a pioneer in advancing health through groundbreaking microbiome solutions. We are a first mover in the field of microbiome solutions for functional dyspepsia with DUOSPORE®, and have launched a diverse portfolio to effectively support people with various needs.
Our commitment is to bring innovative solutions and continue our development efforts. We work together with academic research labs in Belgium to develop new solutions for unmet needs as for example the treatment of Functional Dyspepsia and Recurrent Vulvovaginal Candidiasis (RVVC).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117583860/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip Ranked in Top 25 of Fortune's Europe's Most Innovative Companies 202618.6.2026 10:11:00 CEST | Press release
A strong result highlighting Infobip’s momentum in European tech innovation Global AI-first cloud communications platform Infobip has been ranked in the top 25 of Fortune's Europe's Most Innovative Companies 2026, marking a strong rise on this year's list. The announcement was made at VivaTech in Paris. Last year, Infobip entered Fortune's inaugural ranking at number 68. This year, it climbs to 16! The Fortune Europe's Most Innovative Companies list, in partnership with the global research firm Statista, evaluates companies based on innovation culture, product development, and process improvements. Infobip's rise reflects the accelerating momentum behind its AI-first strategy, including the launch of Infobip AgentOS, its AI-native fully managed solution that orchestrates autonomous AI-driven customer journeys at scale. Infobip's innovation credentials are further reinforced by its role in Important Project of Common European Interest (IPCEI) for Next Generation Cloud Infrastructure and
Philip Morris International Announces New Regional Leadership18.6.2026 10:00:00 CEST | Press release
The appointments strengthen the company’s leadership pipeline as it moves towards a smoke‑free future Philip Morris International (PMI) (NYSE: PM) announced a series of regional leadership appointments that support its ongoing shift toward a smoke‑free future. Effective August 1, 2026, Marco Hannappel has been appointed President, Europe Region, and Can Kuterdem has been appointed President, Latin America & Canada Region. These appointments build on PMI’s evolved organizational model announced in late 2025, under which Gijs de Best serves as President, South Asia, Indochina, CIS & Middle East & Africa Region, and Vassilis Gkatzelis continues as President East & Southeast Asia, Pacific and PMI Global Travel Retail Region. The four regional presidents report to Frederic de Wilde - CEO of the International Business Unit of PMI and are the key operational leaders for the unit that generates the large majority of total PMI net revenues. Marco Hannappel takes over the role of President, Euro
Blooming Future Launches Operations as Part of Braskem’s Expanding Sustainable Fleet18.6.2026 10:00:00 CEST | Press release
Designed for long-range transport of essential raw materials, Blooming Future strengthens Braskem’s commitment to safer, more efficient, and lower-emission shipping. Braskem (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK), the largest polyolefins producer in the Americas and global leader in the production of biopolymers on an industrial scale announces today that Braskem Trading & Shipping (BT&S) has launched the maiden voyage of Blooming Future, a next-generation LR1 chemical and product oil tanker designed to transport essential raw materials with greater efficiency and a lower carbon footprint. The vessel was formally named at a ceremony in China on May 8. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618295583/en/ Braskem's Blooming Future “Blooming Future will carry naphtha to support our industrial production, while operating at optimized speed to reduce fuel consumption and emissions. The vessel is as wid
New Industry Study Finds Quantum Computing Has Entered a Capability Era, With Early Movers Building an Advantage Later Entrants Will Struggle to Close18.6.2026 09:00:00 CEST | Press release
State of Quantum 2026, based on tracked transaction data, a survey of 107 practitioners, and 19 interviews, finds 89% of enterprises surveyed are now hands-on with quantum but only 3% have reached scaled deployment, as the market shifts from accessing quantum systems to building capability around them. Quantum computing has moved past the question of whether organizations can access a quantum system and onto whether they can build something useful around one. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618639340/en/ State of Quantum 2026 is based on independently conducted research and analysis, authored by The Quantum Insider (Resonance), published by IQM Quantum Computers, and supported by OpenOcean. According to the State of Quantum 2026, the fourth annual industry study published today by IQM Quantum Computers, which is nearing its planned listing on the Nasdaq Global Select Market through its merger with Real Asse
Climate Clock Public Art Trail Opens Across Oulu18.6.2026 08:45:00 CEST | Press release
A major contemporary public art trail exploring climate, time and nature has opened across the Oulu region in Northern Finland as part of Oulu2026 European Capital of Culture. The permanent Climate Clock art trail brings together seven internationally recognised artists in site-specific works across forests, rivers, coastlines, urban environments and cultural heritage sites. The works reflect on climate change and different perceptions of time through sculpture, ceramics, natural materials, sound and kinetic forms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617018262/en/ Antti Laitinen – You Are Here (2026), Maija Laitinen/Oulu2026 Already attracting international attention, Climate Clock offers a new public art experience connecting art, science and the northern landscape across the region. The trail opened to the public on 13 June 2026 across six locations: Yli-Ii, Oulu city centre, Ylikiiminki, Oulunsalo, Kiiminki
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom